You can buy or sell Eisai and other stocks, options, ETFs, and crypto commission-free!
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. Read More The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan. ESALY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).
52 Week High
52 Week Low
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
TOKYO, July 14, 2020 - (JCN Newswire) - The Alzheimer's Clinical Trials Consortium (ACTC), Eisai Co., Ltd., and Biogen Inc. announced today that a new Phase III
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded
Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120 TOKYO, July 13, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that i
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Eisai Co., Ltd. Public Relations: +81-(0)3-3817-5120 Merck & Co., Inc., Kenilworth, N.J., U.S.A. Media Relations Pamela Eisele: (267) 305-3558 Michael Close: (2